Phenotypic Drug Discovery : Case Study - Identifying Treatments For Spinal Muscular Atrophy

Phenotypic Drug Discovery : Case Study - Identifying Treatments for Spinal Muscular Atrophy (SMA)

European Federation for Medicinal Chemistry

Phenotypic Drug Discovery: Case Study - Identifying New Druggable Targets in the Wnt-pathway

European Federation for Medicinal Chemistry

Phenotypic Drug Discovery - Webinar (Part One)

European Federation for Medicinal Chemistry

Phenotypic Screening | Phenotypic Drug Discovery |

Phenotypic Drug Discovery - Webinar (Part Two)

European Federation for Medicinal Chemistry

Spinal Muscular Atrophy (SMA) Research Update

UW School of Medicine and Public Health

Identifying, diagnosing and treating patients with later-onset SMA

Touch Medical Media

An Update on Spinal Muscular Atrophy Current Treatment Paradigms and Ongoing Research

MDA

KS Insights: Phenotypic Drug Discovery

KeystoneSymposia

Basics of Phenotypic Screening

RITCH JOSHUA VILLADAREZ

Spinal Muscular Atrophy 2019: Pre symptomatic Spinal Muscular Atrophy

Spinal Muscular Atrophy 2019: Infantile Onset Spinal Muscular Atrophy

Considerations for the selection of disease-modifying treatments in SMA: A case-based discussion

Touch Medical Media

2020 Science Writers' Boot Camp: New Treatments for Spinal Muscular Atrophy—Neurodegenetic Diseases

Johns Hopkins Medicine

Hit Generation: Case Study - Factor D Hit Generation

European Federation for Medicinal Chemistry

Spinal Muscular Atrophy 2019: Clinical Evaluations & Assessments for Spinal Muscular Atrophy

Spinal Muscular Atrophy 2020: Evolving SMA Phenotypes: Sitters across the life span

Considerations for the selection of disease-modifying treatments in SMA: A case-based discussion

Touch Medical Media

Dr. Pannie Trifillis "Drug development in Duchenne Muscular Dystrophy & Spinal Muscular Atrophy ”